Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biodesix (BDSX) Common Equity (2019 - 2026)

Biodesix filings provide 8 years of Common Equity readings, the most recent being $9.1 million for Q1 2026.

  • On a quarterly basis, Common Equity fell 17.43% to $9.1 million in Q1 2026 year-over-year; TTM through Mar 2026 was $9.1 million, a 17.43% decrease, with the full-year FY2025 number at -$2.5 million, down 111.81% from a year prior.
  • Common Equity hit $9.1 million in Q1 2026 for Biodesix, up from -$2.5 million in the prior quarter.
  • In the past five years, Common Equity ranged from a high of $36.3 million in Q2 2024 to a low of -$7.0 million in Q2 2023.
  • Median Common Equity over the past 5 years was $4.6 million (2023), compared with a mean of $7.7 million.
  • The widest YoY moves for Common Equity: up 2026.49% in 2024, down 220.92% in 2024.
  • Biodesix's Common Equity stood at $20.6 million in 2022, then tumbled by 77.77% to $4.6 million in 2023, then surged by 355.81% to $20.9 million in 2024, then crashed by 111.81% to -$2.5 million in 2025, then surged by 470.47% to $9.1 million in 2026.
  • The last three reported values for Common Equity were $9.1 million (Q1 2026), -$2.5 million (Q4 2025), and -$1.7 million (Q3 2025) per Business Quant data.